BP Lipid 308 has a terminal tertiary amine group, a linoleic group, and a 4,4-bis(octyloxy)butanoic acid sodium salt tail. This compound can be useful for the building or modification of lipid nanoparticles. Reagent grade, for research use only.

BP Lipid 314 is an ionizable amino lipid featuring a dimethylamino head group, a carbamate linking to a central tertiary carbon with two other branches, a linoleate ester, and an aliphatic acetal ester. A compound like this may be employed in the development of lipid nanoparticles for drug delivery.

BP Lipid 310 is an ionizable aminolipid analog of CL1. The structure features an ethanolamine head and an ester linking to a polyunsaturated hydrophobic tail. This lipid may be used to encapsulate nucleic acids or small-molecule drugs to form lipid nanoparticles for drug discovery.

BP Lipid 323 is an ionizable aminolipid analog of CL1 which features a unique azetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 321 is an ionizable aminolipid analog of CL1 which features a unique 3-hydroxyazetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 322 is a multichargeable lipid analog of CL1 which features a novel 2-hydroxyethyl piperazine ionizable head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

Al-28 is a multi-ionizable aminolipid featuring a central amine and three identical disulfide-linked saturated side chains. The hydrophobic side chains are linked to the central structure by ester as well as disulfide bonds. Disulfide bonds are readily cleaved in the reducing environment of the cell cytoplasm. Ionizable lipids are typically used in the design of nucleic acid lipid nanoparticles, as their pH-dependent positive charge stabilizes the anionic nucleic acids they encapsulate.

9A1P9 is a multi-tail ionizable cationic phospholipid. 9A1P9 induces membrane destabilization. 9A1P9 can be used for CRISPR-Cas9 gene editing in mice.

ALC-0315 analogue-1 (compound P-10) is a cationic lipid. ALC-0315 analogue-1 is the raw material for synthesis of cationic liposome.

BLU-451, also known as LNG-451, orally bioavailable, central nervous system (CNS) penetrating, mutant-selective covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) activating mutations, with potential antineoplastic activity. Upon oral administration, EGFR Ex20ins inhibitor BLU-451 selectively targets, irreversibly binds to and inhibits the activity of EGFR Ex20ins and some other oncogenic point mutations. This prevents EGFR Ex20ins-mediated signaling. This may induce cell death and inhibit tumor growth in EGFR Ex20ins-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumors, plays a key role in tumor cell proliferation and tumor vascularization. BLU-451 is able to penetrate the blood-brain-barrier (BBB) and may therefore exert its activity against EGFR Ex20ins-driven CNS primary tumors and CNS metastases. BLU-451 does not inhibit the activity of wild-type (WT) EGFR. EGFR Ex20ins are oncogenic driver mutations that constitutively upregulate kinase activity.

VK-2019 is a selective EBNA1 inhibitor. VK-2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV-associated carcinomas. EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells.

PDE4B-IN-2 is an orally active and selective PDE4B inhibitor with an IC50 of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC50=1.7 µM). PDE4B-IN-2 exhibits potent anti-inflammatory effects.

PRMT5 inhibitors; PRMT5 inhibitors;

NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.

UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2.